An experimental drug targeting Ras-driven cancers has delivered unprecedented results against pancreatic cancer, offering new hope for patients with one of the deadliest and most treatment-resistant cancers. Researchers have called the findings one of the most significant advances in cancer treatment in the past 15 years. Whitehead Valhalla Fellow Tobiloba Oni studies pancreatic cancer with a focus on the tumor microenvironment: the complex network of immune cells, structural proteins, and othe
The Verdict
ClassificationUnsure
ConfidenceMedium confidence
Analyzedtext
Community Verdict
Sign in to vote
Be the first to vote on this assessment.
Embed Badge
Add this badge to your site to show the AI classification for this content.
[](https://real.press/content/3a995228-c5e9-4234-8284-c035358a70fc)